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Introduction: The efficacy of erlotinib in advanced non-small-cell lung cancer has been demonstrated in several
trials, but only two cases of complete and prolonged response in wild-type epidermal growth factor receptor locally
advanced lung cancer have been published.
Case presentation: We discuss a case of a 67-year-old Caucasian man, a former heavy cigarette smoker, with a
diagnosis of wild-type epidermal growth factor receptor locally advanced adenocarcinoma. After platinum-based
doublet chemotherapy, when a progression of disease had occurred, a second-line therapy with erlotinib was
started. We observed a progressive reduction of his lung lesion during erlotinib treatment until there was a
complete clinical response.
Conclusions: This case is interesting for the choice of second-line treatment in non-small-cell lung cancer and,
moreover, for the possibility of a complete and prolonged response to erlotinib even in patients without the
activating mutation of epidermal growth factor receptor.
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Lung cancer is one of the most common types of cancer
and the leading cause of human cancer deaths worldwide
[1]. The majority of the cases (85%) are classified as non-
small-cell lung cancer (NSCLC), often diagnosed at an ad-
vanced stage with poor prognosis. Platinum-based doublet
chemotherapy has become the standard of care for the
treatment of advanced or metastatic NSCLC with wild-type
or unknown epidermal growth factor receptor (EGFR) sta-
tus [2].
EGFR-targeted therapy constitutes a new treatment
opportunity.
The EGFR tyrosine kinase inhibitors (TKIs) gefitinib
and erlotinib block signal transduction pathways and* Correspondence: nando.riccardi@alice.it
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unless otherwise stated.inhibit cancer cell survival and proliferation. NSCLC
with activating mutations of the EGFR tyrosine kinase
are highly sensitized to the effects of oral TKIs.
Erlotinib has demonstrated efficacy in the first-line treat-
ment of EGFR mutation-positive NSCLC [3,4]. Several clin-
ical trials have also demonstrated that erlotinib improves
progression-free survival (PFS) and overall survival (OS) in
the second- and third-line treatment of NSCLC [5] as well
as in the maintenance setting [6]. It is known that a muta-
tion in the EGFR gene, clinical characteristics like female
sex, non-smoking status and Asian ethnicity, adenocarcin-
oma histology and skin toxicity reported during the treat-
ment, give an increased response to EGFR inhibitors.
Here, we describe a complete response to erlotinib treat-
ment in a male former heavy cigarette smoker with wild-
type EGFR adenocarcinoma. Therefore, it appears that
treatment with the TKI erlotinib may possibly confer atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion status and other clinical features.
Case presentation
A 67-year-old Caucasian man, a former heavy cigarette
smoker, presented to our hospital with a persistent cough.
He had a medical history of ischemic heart disease, chronic
obstructive pulmonary disease (COPD) and arterial hyper-
tension. A whole-body computed tomography (CT) scan
demonstrated a solid nodule with speculated margins,
measuring approximately 33×33mm, in the apical segment
of his left lower lobe and an infiltration of the pleura and
of pulmonary vessels. Enlarged ipsilateral peribronchial
lymph nodes (24mm) and some small lymph nodes of the
aortopulmonary window were also described. A broncho-
scope image showed only hyperemic inflamed mucosa and
cytology did not provide a cancer diagnosis. Therefore, a
CT-guided fine-needle aspiration biopsy of his pulmonary
nodule was performed. Histology and mutation testing
revealed that the tumor was a wild-type EGFR adenocarcin-
oma (thyroid transcription factor-1 positive). A radical sur-
gery of the lung lesion was excluded because of a chronic
obstructive pulmonary disease. The patient started a first-
line cisplatin-gemcitabine chemotherapy obtaining a partial
response after six courses: a whole body CT scan revealed a
reduction of his lung lesion (12mm versus 33mm) and of
peribronchial lymph nodes (18mm versus 24mm). In view
of the inoperability, he was subsequently treated with radi-
ation therapy gaining a further reduction of the lung lesion
and metastatic lymph nodes. However, 8 months later, a
CT scan established disease progression: the lung nodule
increased to 19 mm (Figure 1), whereas his lymph nodes
appeared stable. The short disease progression-free interval
and the clinical history of this patient ruled out the use of a
new chemotherapy; a second-line therapy with erlotinib at
a dose of 150mg/day was started May 2012. A CT scan
performed after 4 months of erlotinib treatment showed a
reduction of pulmonary lesion volume (Figure 2) and theFigure 1 Computed tomography scan performed before starting
erlotinib treatment.treatment was continued. Four months later, a new CT
scan exhibited a significant reduction of the tumor in the
lower lobe of his left lung (7mm; Figure 3). Finally, in the
last CT scan an area of parenchymal dysventilation in the
apical segment of the lower lobe of his left lung was recog-
nized, while the neoplastic mass was no longer visible
(Figure 4), confirming a complete remission after 1 year of
the erlotinib therapy. In view of the surprising response to
TKI treatment, we also performed a fluorescence in situ
hybridization (FISH) analysis for EGFR, but this test did
not reveal a gene amplification or high polysomy. The
treatment with erlotinib was well tolerated; in fact, the
only adverse event was a grade 1 skin rash on his face,
which occurred early in the treatment and regressed after
4 weeks with a topical therapy. At the time that this article
was revised, our patient was still undergoing treatment
and he was free of disease.
Discussion
Lung cancer is often diagnosed after development of the
late stage disease [7] and palliative chemotherapy is
associated with a modest survival benefit and improved
quality of life (QoL) [8,9]. Platinum-based doublet chemo-
therapy (with agents such as gemcitabine, taxanes, vino-
relbine, pemetrexed and bevacizumab) represents the
standard of care for the treatment of locally advanced or
metastatic NSCLC with wild-type or unknown epidermal
growth factor receptor (EGFR) status [2]. During recent
years, the study of the molecular characteristics of NSCLC
has highlighted the specific role of certain genes. The Erb
family of cell membrane receptors comprises the EGFR
which is involved in cell proliferation, differentiation, and
survival [10]. Activating EGFR mutations (exon 19 deletion
or exon 21 substitution) are predictive for response to the
EGFR-TKIs, gefitinib and erlotinib. These molecules, ultim-
ately approved for the treatment of advanced NSCLC, have
changed the clinical outcome of these malignancies. The in-
cidence of EGFR mutations in the Caucasian population isFigure 2 First evaluation performed after 4 months of treatment
with erlotinib.
Figure 3 A computed tomography scan performed 8 months
after starting treatment with erlotinib.
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adenocarcinoma subtype, and in women. In comparison,
the prevalence of this mutation is the highest in East Asian
patients (approximately 40%). Several randomized trials
have shown that TKIs provide an improved response rate
(RR) and PFS, exhibiting a good tolerability of treatment
and a better QoL, when compared with chemotherapy
as first-line therapy. Indeed, EGFR-TKIs represent the
standard first-line treatment for EGFR-mutated advanced
NSCLC [3,4].
Although EGFR mutations can account for most of the
responses to EGFR-TKIs therapy, the clinical benefits can-
not only be explained by these mutations. Therefore, closer
care should be delivered to patients with wild-type EGFR
with the aim to determine whether or when they should re-
ceive EGFR-TKI treatment. The EGFR gene, in fact, may
undergo polysomy and/or amplification, as detected by
FISH. In addition to mutated EGFR, there is now evidence
that increased EGFR gene copy number, as defined as amp-
lification (ratio≥2, ≥15 copies of EGFR gene in ≥10% of the
cells, the EGFR gene clusters) or high EGFR polysomy (≥4Figure 4 A computed tomography scan performed 1 year after
starting treatment with erlotinib and showing a complete
response.copies of the EGFR gene in ≥40% of cells), is associated
with a better response to gefitinib and erlotinib [11,12].
The results from the BR.21 trial [5,13] suggested that pa-
tients with increased EGFR gene copy number may have
longer survival (BR. 21: hazard ratio, HR, 0.43, 95% confi-
dence interval 0.23 to 0.78, p<0.004). Therefore, further re-
search is needed to refine the potential impact of the
number of mutated copies of the EGFR gene as the factor
modifying prospective benefits of TKI treatment.
Regarding second-line therapy, treatment options consist
of pemetrexed [14] limited to the non-squamous histology,
docetaxel [15] or erlotinib [5]. The BR.21 trial was designed
to compare erlotinib (in second- and third-line treatment
or patients not eligible for further chemotherapy) with best
supportive care in 731 patients with advanced NSCLC. In
this study, patients treated with erlotinib had a RR of 8.9%,
a statistically significant increase in median (6.7 versus 4.7
months) and 1-year survival rate (31% versus 21%) com-
pared to the patients receiving a placebo, and this benefit
was similar across multiple subgroups. Moreover, smoking
status appeared to be the most powerful predictor of a sur-
vival effect with erlotinib: never-smokers receiving erlotinib
had a significantly higher survival rate than patients in the
placebo arm (HR, 0.4; p <0.01) [16]. This randomized trial
demonstrated erlotinib can prolong survival after chemo-
therapy and can give significant benefits in QoL and lung
cancer-related symptoms of cough, dyspnea and pain [13].
The safety and efficacy profile of erlotinib has been con-
firmed by a phase IV study (Tarceva Lung Cancer Survival
Treatment (TRUST)) in a heterogeneous NSCLC popula-
tion including more than 6500 patients. This trial included
patients with advanced stage IIIB/IV NSCLC who had pre-
viously failed on or were considered unsuitable to receive
standard chemotherapy or radiotherapy and were ineligible
for other erlotinib trials. In patients with advanced NSCLC,
the PFS and OS in this study were 3.25 months and 7.9
months, respectively, and the disease control rate was 69%.
Results from the TRUST study suggested that erlotinib can
benefit a wide range of patients, including those who have
previously been thought unlikely to respond to this treat-
ment [17].
Previous data have been reinforced, finally, by the TITAN
trial showing that erlotinib is equivalent to pemetrexed or
docetaxel in refractory patients progressing during the four
cycles of a standard platinum-based chemotherapy doublet
[18]. However, more recently, the TAILOR trial results
show that chemotherapy is more effective than erlotinib for
second-line treatment for previously treated patients with
NSCLC who have wild-type EGFR tumors. Median OS (8.2
months with docetaxel versus 5.4 months with erlotinib)
and PFS (2.9 versus 2.4) were significantly better with doce-
taxel than with erlotinib [19].
In this trial, only 3% of patients had a partial response
to erlotinib, and it is possible that there are determinants
Vitale et al. Journal of Medical Case Reports 2014, 8:102 Page 4 of 5
http://www.jmedicalcasereports.com/content/8/1/102other than EGFR mutations of erlotinib efficacy that
have yet to be fully validated. Potential biomarkers in-
clude EGFR amplification and/or presence of EGFR li-
gands. However, given the low RR, these are likely to
exist in only a small subset of EGFR wild-type NSCLC
patients.
Although evidence of the TAILOR trial indicated the
superiority of using chemotherapy in a second-line to
treat patients who were EGFR mutation-negative, further
study is required to verify that for patients who are
EGFR FISH positive it may be favorable to choose
EGFR-TKIs or chemotherapy treatment in EGFR wild-
type population considering improved QoL and tolerable
toxicity. A combined analysis of EGFR FISH and muta-
tion is an effective predictor of EGFR-TKI therapy. Spe-
cifically, EGFR gene copy number should be further
detected in patients with wild-type EGFR, because a high
EGFR copy number may predict a greater benefit from
TKIs treatment.
Erlotinib has a good safety profile and main toxicities
are skin rash and diarrhea. Skin rash has been confirmed
as an independent predictive factor for progression (HR
0.50, p<0.00001) and survival (HR 0.30, p<0.0001) in
TKI-treated NSCLC patients. Patients who developed
grade 2 to 4 skin rash were more likely to respond to
the treatment (42%) compared to those who did not
(7%). Thus, skin rash development has been strongly
correlated with EGFR-TKI efficacy [20]. Our patient de-
veloped grade 1 skin rash that regressed completely after
a month with topical therapy.
Therefore, the characteristics of this patient (Caucasian
ethnicity, male gender, cigarette smoking history and no
severe skin rash) did not represent the well-known predic-
tors of best response to EGFR-TKIs.
Nevertheless, our patient has achieved not only a
complete response, but he has also exceeded the median
OS and PFS recorded in the BR.21 trial.
Conclusions
To the best of our knowledge, there are only two cases
described in the literature of a complete response to
second-line therapy with erlotinib in EGFR wild-type
NSCLC [21,22].
The TKI erlotinib confers a benefit in terms of RR,
PFS and OS, in patients with NSCLC, and this benefit
can appear even regardless of EGFR mutation status,
clinical characteristics and skin toxicity.
In patients with progressive NSCLC after failure of
standard chemotherapy, a second-line treatment with er-
lotinib should be considered in view of the good safety
profile, easy administration and possibility of a long
treatment period with a good QoL.
The choice of erlotinib at disease progression, instead
of second-line chemotherapy, could be preferable forpatients with co-morbidities and for patients which have
a low probability of a response to a cytotoxic treatment.
In the present case report, the choice of erlotinib in
second line of treatment exhibited a surprising response,
because the clinical characteristics of our patient did not
correlate with those predictive of response or benefit.
Despite the negative EGFR mutational test and only a
mild and transient skin rash, the clinical efficacy of the
TKI continued for several months keeping a complete
response.
The clinical response has been complete and prolonged.
In fact, in the BR.21 trial the OS and the PFS have been
6.7 and 2.2 months, respectively, in the erlotinib-treated
subset, therefore, our patient has already exceeded those
periods of time gaining a survival benefit. Finally, from this
we suggest that no assumptions should be made on the
EGFR test in the choice of second-line treatment for
advanced NSCLC.
Despite our knowledge, further studies are needed on
the EGFR pathway, with focus on unknown pathways
that could be altered and activated from a platinum-
based chemotherapy.Consent
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